Logo image of LXEO

LEXEO THERAPEUTICS INC (LXEO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LXEO - US52886X1072 - Common Stock

9.35 USD
+0.26 (+2.86%)
Last: 12/5/2025, 8:00:00 PM
9.35 USD
0 (0%)
After Hours: 12/5/2025, 8:00:00 PM
Fundamental Rating

2

Taking everything into account, LXEO scores 2 out of 10 in our fundamental rating. LXEO was compared to 531 industry peers in the Biotechnology industry. LXEO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LXEO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LXEO has reported negative net income.
LXEO had a negative operating cash flow in the past year.
LXEO had negative earnings in each of the past 5 years.
In the past 5 years LXEO always reported negative operating cash flow.
LXEO Yearly Net Income VS EBIT VS OCF VS FCFLXEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -72.97%, LXEO is not doing good in the industry: 63.36% of the companies in the same industry are doing better.
LXEO has a Return On Equity (-86.87%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -72.97%
ROE -86.87%
ROIC N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
LXEO Yearly ROA, ROE, ROICLXEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LXEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LXEO Yearly Profit, Operating, Gross MarginsLXEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for LXEO has been increased compared to 1 year ago.
The debt/assets ratio for LXEO has been reduced compared to a year ago.
LXEO Yearly Shares OutstandingLXEO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
LXEO Yearly Total Debt VS Total AssetsLXEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

An Altman-Z score of 12.61 indicates that LXEO is not in any danger for bankruptcy at the moment.
The Altman-Z score of LXEO (12.61) is better than 84.30% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that LXEO is not too dependend on debt financing.
LXEO has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.61
ROIC/WACCN/A
WACCN/A
LXEO Yearly LT Debt VS Equity VS FCFLXEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 7.40 indicates that LXEO has no problem at all paying its short term obligations.
LXEO has a better Current ratio (7.40) than 72.15% of its industry peers.
LXEO has a Quick Ratio of 7.40. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.40, LXEO is doing good in the industry, outperforming 72.34% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.4
Quick Ratio 7.4
LXEO Yearly Current Assets VS Current LiabilitesLXEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.29% over the past year.
EPS 1Y (TTM)14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

LXEO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.18%
EPS Next 2Y21.6%
EPS Next 3Y12.89%
EPS Next 5Y16.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LXEO Yearly Revenue VS EstimatesLXEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2029 2030 2031 2032 100M 200M 300M 400M 500M
LXEO Yearly EPS VS EstimatesLXEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LXEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LXEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXEO Price Earnings VS Forward Price EarningsLXEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXEO Per share dataLXEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as LXEO's earnings are expected to grow with 12.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.6%
EPS Next 3Y12.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXEO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (12/5/2025, 8:00:00 PM)

After market: 9.35 0 (0%)

9.35

+0.26 (+2.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-24 2026-03-24/bmo
Inst Owners81.45%
Inst Owner Change19.11%
Ins Owners0.42%
Ins Owner Change1.74%
Market Cap682.46M
Revenue(TTM)N/A
Net Income(TTM)-104.97M
Analysts87.5
Price Target19.79 (111.66%)
Short Float %8.28%
Short Ratio4.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.64%
Min EPS beat(2)13.49%
Max EPS beat(2)37.78%
EPS beat(4)3
Avg EPS beat(4)8.16%
Min EPS beat(4)-23.91%
Max EPS beat(4)37.78%
EPS beat(8)5
Avg EPS beat(8)0.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.07%
PT rev (3m)11.31%
EPS NQ rev (1m)23.2%
EPS NQ rev (3m)36.48%
EPS NY rev (1m)20.82%
EPS NY rev (3m)24.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.65
P/tB 5.65
EV/EBITDA N/A
EPS(TTM)-2.7
EYN/A
EPS(NY)-1.61
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0
BVpS1.66
TBVpS1.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -72.97%
ROE -86.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.4
Quick Ratio 7.4
Altman-Z 12.61
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)146.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.92%
EPS Next Y34.18%
EPS Next 2Y21.6%
EPS Next 3Y12.89%
EPS Next 5Y16.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.66%
EBIT Next 3Y-9.58%
EBIT Next 5YN/A
FCF growth 1Y-36.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.4%
OCF growth 3YN/A
OCF growth 5YN/A

LEXEO THERAPEUTICS INC / LXEO FAQ

What is the fundamental rating for LXEO stock?

ChartMill assigns a fundamental rating of 2 / 10 to LXEO.


What is the valuation status for LXEO stock?

ChartMill assigns a valuation rating of 0 / 10 to LEXEO THERAPEUTICS INC (LXEO). This can be considered as Overvalued.


What is the profitability of LXEO stock?

LEXEO THERAPEUTICS INC (LXEO) has a profitability rating of 0 / 10.


What is the financial health of LEXEO THERAPEUTICS INC (LXEO) stock?

The financial health rating of LEXEO THERAPEUTICS INC (LXEO) is 5 / 10.